Research programme: scanning unnatural protease resistant peptides - EvoRx

Drug Profile

Research programme: scanning unnatural protease resistant peptides - EvoRx

Alternative Names: EVO-004; SUPR 4; SUPR-18F

Latest Information Update: 22 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EvoRx
  • Developer EvoRx; University of Texas M. D. Anderson Cancer Center
  • Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Computer-assisted image interpretation enhancers; Image enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 20 Sep 2013 EvoRx receives SBIR grant from National Cancer Institute for scanning unnatural protease resistant peptides development in Breast Cancer (Diagnsosis)
  • 01 Jan 2013 Preclinical trials in Breast cancer (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top